Evidence map›Paper›PMID 37857232›Full record

ArticleNeuroImage. Clinical2023

Impact of follow ups, time interval and study duration in diffusion & myelin MRI clinical study in MS.

Manon Edde, Francis Houde, Guillaume Theaud, Matthieu Dumont, Guillaume Gilbert, Jean-Christophe Houde, Loïka Maltais, Antoine Théberge, Moussa Doumbia, Ann-Marie Beaudoin and 4 more

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Manon EddeImeka Solutions, Inc., Sherbrooke, QC, Canada; Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: eddemanon@gmail.com.
Francis HoudeImeka Solutions, Inc., Sherbrooke, QC, Canada.
Guillaume TheaudImeka Solutions, Inc., Sherbrooke, QC, Canada.
Matthieu DumontImeka Solutions, Inc., Sherbrooke, QC, Canada.
Guillaume GilbertMR Clinical Science, Philips Healthcare Canada, Mississauga, Ontario, Canada.
Jean-Christophe HoudeImeka Solutions, Inc., Sherbrooke, QC, Canada.
Loïka MaltaisImeka Solutions, Inc., Sherbrooke, QC, Canada.
Antoine ThébergeUniversité de Sherbrooke, Sherbrooke, QC, Canada; Videos & Images Theory and Analytics Laboratory (VITAL), Université de Sherbrooke, Sherbrooke, QC, Canada.
Moussa DoumbiaUniversité de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.
Ann-Marie BeaudoinUniversité de Sherbrooke, Sherbrooke, QC, Canada; Université de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.
Emmanuelle LapointeUniversité de Sherbrooke, CIUSSS de l'Estrie-CHUS Fleurimont, Sherbrooke, QC, Canada.
Muhamed BarakovicRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel Switzerland, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Stefano MagonRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel Switzerland, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Maxime DescoteauxImeka Solutions, Inc., Sherbrooke, QC, Canada; Université de Sherbrooke, Sherbrooke, QC, Canada.
Université de Sherbrooke · CARoche (Switzerland) · CHCARE Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is currently unknown how quantitative diffusion and myelin MRI designs affect the results of a longitudinal study. We used two independent datasets containing 6 monthly MRI measurements from 20 healthy controls and 20 relapsing-remitting multiple sclerosis (RR-MS) patients. Six designs were tested, including 3 MRI acquisitions, either over 6 months or over a shorter study duration, with balanced (same interval) or unbalanced (different interval) time intervals between MRI acquisitions. First, we show that in RR-MS patients, the brain changes over time obtained with 3 MRI acquisitions were similar to those observed with 5 MRI acquisitions and that designs with an unbalanced time interval showed the highest similarity, regardless of study duration. No significant brain changes were found in the healthy controls over the same periods. Second, the study duration affects the sample size in the RR-MS dataset; a longer study requires more subjects and vice versa. Third, the number of follow-up acquisitions and study duration affect the sensitivity and specificity of the associations with clinical parameters, and these depend on the white matter bundle and MRI measure considered. Together, this suggests that the optimal design depends on the assumption of the dynamics of change in the target population and the accuracy required to capture these dynamics. Thus, this work provides a better understanding of key factors to consider in a longitudinal study and provides clues for better strategies in clinical trial design.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingBrainDiffusion Magnetic Resonance ImagingFollow-Up StudiesHumansLongitudinal StudiesMagnetic Resonance ImagingMyelin SheathDiffusion MRIFollow-upsHealthy controlsInhomogeneous magnetization transferLongitudinal studyMultiple SclerosisStudy durationTime-interval

Identifiers

PMID37857232
PMCPMC10591008
OpenAlexW4387519905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.